Navigation Links
Studies in Medical Technology

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co.,...

PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies

MIDLOTHIAN, Va., June 30 /PRNewswire/ -- In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors (Ultra and Ultra II) were used to show that nebulized formoterol fumarate (Perforomist, DEY LP, Mylan Inc.) improves pulmonary function. "We are pleased th...

School of Dentistry Studies Link Between Oral Health and Memory

MORGANTOWN, W.Va., June 19 /PRNewswire-USNewswire/ -- Keeping your teeth brushed and flossed can cut down on gum disease, drastically reducing risk of heart attack and stroke, dentists have warned for years. Now researchers at West Virginia University have found a clean mouth may also help prese...

Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells

Therapy targets folate receptors found on cancer cells otherwise resistant to standard chemo ZION, Ill., June 17 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, a leading provider of innovative cancer care for patients living wi...

New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring

IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that three new independent studies demonstrating the clinical accuracy and utility of Masimo PVI as a nonin...

Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

-Second Data Set Presented at MDS- PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented...

Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery

Studies Advocate Blood Conservation and Appropriate Indicators for Transfusion IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that two new studies - ...

Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox

CINCINNATI, June 3 /PRNewswire/ -- Ethicon Endo-Surgery, Inc. today announced that multiple studies presented at the 2009 Digestive Disease Week (DDW) demonstrate the company's novel, investigational* Toolbox enables natural orifice translumenal endoscopic surgery (NOTES) procedures without lap...

Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients

The results of these studies will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009 COLUMBIA, Md., May 31 /PRNewswire/ -- A study conducted at Westchester Medical Center in Valhalla, NY examined liver transplant recipients to determine whether the use o...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...

VA Studies Advanced Prosthetic Arm

New Mobility for Veterans, Service Members, Other Americans WASHINGTON, May 27 /PRNewswire-USNewswire/ -- The Department of Veterans Affairs (VA) has announced a three-year study of an advanced artificial arm that easily allows those with severe limb loss to pick up a key or hold a pencil. ...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

Positive Results Based on New DSCG Formulation & eFlow Technology Delivery MUNICH and MONTEREY, Calif., May 20 /PRNewswire/ -- This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients - - Results of new analyses of efficacy and safety reported - - Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) - SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN...

Autism Studies Presented at Mid-Atlantic Research Consortium Meeting

PHILADELPHIA, May 8 /PRNewswire-USNewswire/ -- Science is largely a collaborative enterprise. Frequently researchers from various disciplines but with some common interests pool their efforts and exchange ideas, to devise new avenues of investigation. When unraveling complex conditions such as tho...

New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug

- Four of the most commonly used proton pump inhibitors raise risk of heart attack and stroke for patients taking Plavix(R) and increase healthcare costs - Drug interaction increases annual hospital costs by nearly 40 percent FRANKLIN LAKES, N.J., May 6 /PRNewswire-FirstCall/ -- Four ...

New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

Data indicated comparable efficacy and safety for extended release and immediate release formulations of pramipexole SEATTLE, April 29 /PRNewswire/ -- New findings from two double-blind studies investigating the efficacy, safety and tolerability of pramipexole dihydrochloride tablets in an ...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

- Company will increase focus on HCV pipeline - Conference call at 8:00 AM ET today PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that after a discussion with its independent Data Safety Monitoring Board (DSMB) and the FDA, the co...

Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout

ATLANTA, April 8 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended...

Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX

Findings Demonstrate Statistically Significant Improvements in Skin Tightening and Tissue Shrinkage; Data to be Presented at 2009 American Society for Laser Medicine and Surgery Annual Conference WESTFORD, Mass., April 2 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO ) today an...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1--Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell ...

Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.

SAN DIEGO, March 10 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies are expected to be available in...

Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield

100% Technical Success, No Peri-procedural Complications Reported With Coronary Device DOYLESTOWN, Pa., March 4 /PRNewswire/ -- Prescient Medical, Inc. reached a crucial milestone in February by completing the enrollment of 30 patients in the first phase of its first-in-human clinical trial f...

Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)

Studies Support Potential for Alzheimer's Disease and Other Neurodegenerative Diseases NEW YORK, March 3 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheim...

BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine

MOUNTAIN VIEW, California, February 23 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. today provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2. The study met...

Oridion Announces Significant Medical Studies Presented at STA

JERUSALEM and NEEDHAM, Massachusetts, February 2 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN). During the recent annual meeting of the Society for Technology in Anesthesia (STA) San Antonio, Texas, major new findings from numerous medical research projects demonst...

Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease

Simultaneous Studies to Investigate Novel Therapy for Ulcerative Colitis and Crohn's Disease OSAKA, Japan, Jan. 22 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") announced today that its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., has initiated two Phase III c...

Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ --IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that verification studies of the IntelligentMDx BK Viral Quantitative Assay are complete. Under the verification protocol the Limit of De...

Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment

PARSIPPANY, N.J., Jan. 6 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that enrollment has been completed in two pivotal Phase III SIMPLE trials to evaluate the safety and efficacy of a single intraoperative administration of EXPA...

MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes

Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD ) will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA(TM), the company's ultra rapid actin...

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

SAN DIEGO, Dec. 14 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, reported today findings from three studies using the company's molecular breast cancer assay to predict risk of disease recurrence in ind...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced results from three studies showing that treatment with Campath(R) (alemtuzumab) showed activity in high-ris...

Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa

NEW ORLEANS, Dec. 8 /PRNewswire/ -- Results published online today in the New England Journal of Medicine revealed that the world's most clinically advanced malaria vaccine candidate provides both infants and young children with significant protection against malaria. Two separate phase II trials ...

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

- In Two Studies Drug was Well-Tolerated, Significantly Inhibited Leukotriene Production, and Reduced Inflammation- - Webcast Conference Call to Discuss Results on Monday, November 10 at 8:30 a.m. ET- NEW ORLEANS and SAN FRANCISCO, Nov. 9 /PRNewswire...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

TAMPA, Fla., Nov. 3 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding eye diseases will be presented at upcoming ophthalmology ...

Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting

IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS ), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies, today announced that four scientific posters featuring both patient cases and laboratory research in which the Thermogard XP...

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

New coronary stent features thin struts designed for more uniform drug delivery NATICK, Mass., and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced comprehensive data from the TAXUS ATLAS clinical program,...

Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children

Award-winning video clips feature children, parents discussing clinical studies BETHESDA, Md., Oct. 6 /PRNewswire-USNewswire/ -- From asthma and cancer treatments to vaccines, research in children saves lives and improves their health and well-being. A new Web si...

New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery

Results Presented at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting CHICAGO, Sept. 24 /PRNewswire/ -- In studies presented this week at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting, researchers found that Coblat...

New Studies Confirm Safety, Effectiveness of Balloon Sinuplasty(TM) Technology for Chronic Sinusitis

Patients show significant improvement through 2-year follow-up MENLO PARK, Calif., Sept. 22 /PRNewswire/ -- Two multicenter studies published this week in Otolaryngology - Head and Neck Surgery confirm Balloon Sinuplasty(TM) technology is safe and effective when used by physicians to trea...

Most Cancer Treatment Studies Aren't Published, Study Finds

Concern Raised about 'Cancer Publication Bias' DURHAM, N.C., Sept. 15 /PRNewswire/ -- Less than 20 percent of registered clinical trials of cancer treatment are eventually published in medical journals, according to a study published online today by the journal "The Oncologist." ...
Other Tags
(Date:4/20/2014)... a gift of germsgerms that help to kick-start ... fend off infection, may paradoxically interrupt a newborn,s ... susceptible to dangerous pathogens. , A new ... Hospital of Philadelphia (CHOP) sheds light on immunology ... a crucial role in fostering the rapid production ...
(Date:4/18/2014)... Protecting wildlife while feeding a world population predicted ... a holistic approach to conservation that considers human-altered ... , Wildlife and the natural habitat that supports ... a world where at least three-quarters of the ... the rest is vulnerable to human-caused impacts such ...
(Date:4/18/2014)... A team of researchers led by a University ... to receive a $7.5 million Department of Defense grant ... basic scientific foundations for the predictable design of light-weight, ... diversity of structures from plants and animals, including the ... what biological systems have constructed over millions of years ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3
(Date:4/20/2014)... in children, codeine continues to be prescribed in U.S. ... Children,s Hospital San Francisco. , As reported in the ... provider prescription behaviors to promote the use of better ... "Despite strong evidence against the use of codeine in ... numbers of them each year," said Sunitha Kaiser, MD, ...
(Date:4/18/2014)... group of scientists from the University of Kentucky ... Aging has found interesting new information in a ... disease (PD). , Published in the journal ... cognitive function in depressed and non-depressed patients with ... used to treat motor symptoms of Parkinson,s disease ...
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Treating depression in PD patients: New research 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3
Other Contents